Skip to main content
Equibles

Nelson Cabatuan

CFO

Lexaria Bioscience Corp. (LEXX)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Nelson Cabatuan

Nelson Cabatuan is recorded as CFO at Lexaria Bioscience Corp. (LEXX). Lexaria Bioscience Corp. reported in an 8-K filed October 2, 2024 that Nelson Cabatuan resigned as Chief Financial Officer, effective July 15, 2024. Lexaria Bioscience Corp. reported in an 8-K filed July 17, 2024 that Nelson Cabatuan resigned as Chief Financial Officer, effective July 15, 2024. Lexaria Bioscience Corp. reported in an 8-K filed March 15, 2024 that Nelson Cabatuan was appointed Chief Financial Officer, effective March 14, 2024.

“Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp. (the "Company") replacing Lexaria's former CFO, Nelson Cabatuan who resigned effective July 15, 2024 and assuming the position of principal financial officer and principal accounting officer previously assumed by the Company's CEO, Richard Christopher.”
Lexaria Bioscience Corp. Form 8-K, filed October 2, 2024 · Read the filing
“Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company's Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.”
Lexaria Bioscience Corp. Form 8-K, filed July 17, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Lexaria Bioscience Corp.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.